#dlbcl — Public Fediverse posts on home.social

Universität zu Köln @[email protected] · 2026-04-24 · 16:21 UTC

🔬cFLIP in the fight against lymphoma
Diffuse large B‑cell lymphoma (#DLBCL) is the most common non‑Hodgkin lymphoma and often relapses despite frontline immunochemotherapy. The research team led by Dr Alessandro Annibaldi at the Center for Molecular Medicine Cologne has identified the key protein cFLIP as the “roadblock” that lets these cancer cells evade both intrinsic and extrinsic apoptosis.

Read more ▶️ https://uni.koeln/2KEN4

#uniköln #unicologne

#dlbcl #unikoln #unicologne

IQWiG @[email protected] · 2023-03-02 · 12:51 UTC

5/

A case study of pivotal trials in #EMA approvals of new cancer treatments in r/r #DLBCL showed that RCTs were available for 2 out of 6 approvals; 4 only had single-arm trials (Table in https://www.bmj.com/content/380/bmj-2022-073100).

However, the number of included patients was similar or even larger in single-arm studies than in RCTs

➡️ using single-arm studies 1️⃣ 💪 💊 does not seem to be related to the size of the patient population, it seems to be a choice rather than a necessity.

#ema #dlbcl

Karine Crozat @[email protected] · 2022-12-12 · 15:05 UTC

First evidence that Tumor-Associated Macrophages interaction with blood endothelial cells is associated to poor prognosis in diffuse large B cell lymphoma

Great work from
#JulietteFerrant #MikaelRoussel

#CyTOF and #scRNAseq of #TAM in #DLBCL
👇

https://www.biorxiv.org/content/10.1101/2022.12.08.519637v1

#julietteferrant #mikaelroussel #cytof #scrnaseq #tam #dlbcl